SCHEMBL895887

SCHEMBL895887

C[C@H]1CCC[C@@H]1N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20841809 1.00
SCHEMBL895999 1.00
SCHEMBL22221765 1.00
SCHEMBL18611199 1.00
SCHEMBL43806 1.00
SCHEMBL895888 1.00
SCHEMBL895537 1.00
Hydrochloric Acid SCHEMBL20574416 0.97
Hydrochloric Acid SCHEMBL20574418 0.97
Hydrochloric Acid SCHEMBL2859458 0.97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9879293-B2 Enzymatic transamination of cyclopamine analogs INFINITY PHARMACEUTICALS, INC. (US) 2018-01-30 US claimed
US-20160177354-A1 ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS SAFC, INC. 2016-06-23 US claimed
EP-2462115-B1 ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS INFINITY PHARMACEUTICALS INC (US) 2016-01-06 EP claimed
US-8703448-B2 Enzymatic transamination of cyclopamine analogs INFINITY PHARMACEUTICALS, INC. (US) 2014-04-22 US claimed
US-20120083607-A1 Enzymatic Transamination of Cyclopamine Analogs INFINITY PHARMACEUTICALS, INC. (US) 2012-04-05 US claimed
WO-2020120450-A1 SUBSTITUTED XANTHINE DERIVATIVES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2020-06-18 WO disclosed
WO-2018097945-A1 HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS AMGEN INC. (US) 2018-05-31 WO disclosed
US-9879293-B2 Enzymatic transamination of cyclopamine analogs INFINITY PHARMACEUTICALS, INC. (US) 2018-01-30 US disclosed
US-9840478-B2 Piperazine derivatives as HIV protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-12-12 US disclosed
US-9751877-B2 Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders PFIZER INC. (US) 2017-09-05 US disclosed
US-9630978-B2 Polycyclic-carbamoylpyridone compounds and their pharmaceutical use GILEAD SCIENCES, INC. (US) 2017-04-25 US disclosed
US-9550788-B2 Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof SANOFI (FR) 2017-01-24 US disclosed
US-20120083607-A1 Enzymatic Transamination of Cyclopamine Analogs INFINITY PHARMACEUTICALS, INC. (US) 2012-04-05 US disclosed
US-20110201590-A1 SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF SANOFI-AVENTIS (FR) 2011-08-18 US disclosed
US-7968534-B2 Sulfonamide derivatives, preparation thereof and use thereof as antagonists of orexin 2 receptors SANOFI-AVENTIS (FR) 2011-06-28 US disclosed
US-7968534-B2 Sulfonamide derivatives, preparation thereof and use thereof as antagonists of orexin 2 receptors SANOFI-AVENTIS (FR) 2011-06-28 US disclosed
WO-2011017551-A1 ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS INFINITY PHARMACEUTICALS, INC. (US) 2011-02-10 WO disclosed
US-20090042851-A1 SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF AS ANTAGONISTS OF OREXIN 2 RECEPTORS SANOFI-AVENTIS (FR) 2009-02-12 US disclosed
US-20090042851-A1 SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF AS ANTAGONISTS OF OREXIN 2 RECEPTORS SANOFI-AVENTIS (FR) 2009-02-12 US disclosed
WO-2007085718-A1 SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2007-08-02 WO disclosed